Tracer library / [131I]MAAN

[131I]MAAN

Also written as [I-131]MAAN

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Gastrointestinal and colorectal cancer Pan-cancer / multiple tumour types

What it is

Compound class: Legumain-responsive self-assembling CBT-Cys condensation-based radiopharmaceutical (small-molecule peptide-based agent)
Target / mechanism: Legumain (asparaginyl endopeptidase), activated in response to legumain and glutathione (GSH) PMID 35297450
Clinical application: Targeted radionuclide therapy for tumors with high legumain expression PMID 35297450
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	57.8 ± 5.3%	>95%	—	35297450 2022 J Mater Chem B

Need this precursor?We can point you to suppliers for [131I]MAAN, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 35297450: 'TRT with [131I]MAAN significantly inhibited the tumor growth and no obvious toxicity towards other normal organs was observed'.